Search

Displaying results 5071 - 5080 of 5896 in total
  1. Drug

    Xeruborbactam

    go.drugbank.com/drugs/DB21512
    Investigational

    Xeruborbactam is under investigation in clinical trial NCT07104162 (A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment).

  2. Drug

    Gridegalutamide

    go.drugbank.com/drugs/DB21593
    Investigational

    Gridegalutamide is under investigation in clinical trial NCT04428788 (Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer).

  3. Drug

    Tamuzimod

    go.drugbank.com/drugs/DB21621
    Investigational

    Tamuzimod is under investigation in clinical trial NCT05156125 (VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis).

  4. Drug

    Merbromin

    go.drugbank.com/drugs/DB13392
    Investigational

    an organomercuric disodium salt compound and a fluorescein that is available in many countries, except Switzerland, France, Germany, and the United States where the drug was withdrawn from market due to

  5. Drug

    VSF-173

    go.drugbank.com/drugs/DB05753
    Investigational

    Study shows that VSF-173 possesses a novel mechanism to address disorders of excessive sleepiness.

  6. Drug

    Sifalimumab

    go.drugbank.com/drugs/DB12773
    Investigational

    Sifalimumab may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients.

  7. Drug

    Linvencorvir

    go.drugbank.com/drugs/DB21544
    Investigational

    Linvencorvir is under investigation in clinical trial NCT04225715 (A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B).

  8. Drug

    Relutrigine

    go.drugbank.com/drugs/DB21614
    Investigational

    Relutrigine is under investigation in clinical trial NCT07010471 (A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine).

  9. Drug

    Bexotegrast

    go.drugbank.com/drugs/DB16515
    Investigational

    PLN-74809 is a small-molecule that dually inhibits both α<sub>v</sub>β<sub>6</sub> and α<sub>v</sub>β<sub>1</sub> to treat both idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC … The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical

  10. Drug

    Cabozantinib

    go.drugbank.com/drugs/DB08875
    ApprovedInvestigational

    Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2...